UBS analyst Danielle Antalffy raised the firm’s price target on Medtronic to $75 from $72 and keeps a Sell rating on the shares. Despite Medtronic’s outperformance in Q4, the firm remains skeptical of the sustainability of new product momentum and tells investors in a research note that commentary suggests FY25 consensus EPS is potentially too high.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Medtronic (NYSE:MDT) Soars on Q3 Beat
- Options Volatility and Implied Earnings Moves Today, February 20, 2024
- Medtronic Reorganizes Units and Executives Depart
- Medtronic raises FY24 EPS view to $5.19-$5.21 from $5.13-$5.19, consensus $5.16
- Medtronic reports third quarter fiscal 2024 financial results
